即時護理 (POC) 診斷市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1273433

即時護理 (POC) 診斷市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Point of Care Diagnostics Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

床旁 (POC) 診斷市場目前價值 380.3 億美元,預計在預測期內將以 9.8% 的複合年增長率增長。

COVID-19 大流行對 POC 診斷市場的增長產生了重大影響。 例如,2022 年 8 月發表在 Cureus 雜誌上的一篇論文報告說,COVID-19 的出現使得測試對於遏制和緩解目的至關重要,從而導致開發出針對 COVID-19 的快速測試。。 因此,COVID-19 大流行激增了對 POC 診斷的需求。 然而,在目前的情況下,由於 POC 診斷的簡便性、可負擔性、較低的並發症發生率和快速的周轉時間,預計在預測期內對 POC 診斷的需求將顯著增長。

慢性病和傳染病患病率的上升、對新免疫測定技術和技術進步的監管批准數量的增加,以及家庭護理點設備使用率的上升,都是推動該市場增長的因素。等等。

糖尿病、類風濕性關節炎和瘧疾等慢性病和傳染病的患病率在全球範圍內不斷上升,這推動了對 POC 診斷的需求。 例如,2022 年 12 月,世界衛生組織 (WHO) 報告稱,瘧疾是一種危及生命的疾病,2021 年全球估計有 2.47 億瘧疾病例。確實如此。 同樣,NCBI 於 2021 年 5 月發表的一篇論文報告稱,2020 年至 2021 年期間,類風濕性關節炎 (RA) 的全球患病率為每 100,000 人 460 人。 因此,全球記錄的大量慢性病和傳染病增加了對快速診斷的需求,這反過來又增加了對 POC 診斷的需求,推動了調查市場的增長。

此外,在預測期內,對新型免疫測定技術的監管批准數量不斷增加、技術進步以及家用 POC 設備使用率的增加預計將補充所研究市場的增長。 例如,2022 年 7 月,BioGX 推出了帶有 CE 標誌的 3 基因多重 POC COVID-19 測試。 這些測試利用了 BioGX 公司的 Xfree COVID-19直接 RT-PCR 分析中存在的極其有效的 Xfree 直接樣品測試化學,該分析已被美國食品和藥物管理局 (USFDA) 批准用於緊急情況。 因此,對新產品發布的監管批准有助於所研究市場的增長。

此外,在 Mylab Discovery Solutions 2022 年 3 月發表的一篇文章中,POC 診斷通常具有獨立於實驗室基礎設施且非常便宜的特點,可以提高診斷的可及性。據悉,它可以大大提高診斷的可及性。改善。 這篇文章還指出,對於生活在醫療保健分佈高度異質性的低收入和中等收入國家的人們來說,POC 檢測的使用正在增長,作為擴大人群診斷覆蓋率的重要工具,從而表明 POC 對檢測的需求不斷增加,這被認為是推動研究市場增長的因素。

因此,慢性病和傳染病的患病率上升,新的監管批准數量不斷增加。 然而,市場巨頭髮生產品召回、各國政府嚴格的監管政策以及報銷問題等因素預計將在預測期內阻礙 POC 診斷市場的增長。

床旁 (POC) 診斷市場趨勢

預計血糖檢測在預測期內將顯著增長。

血糖測試測量血液中的葡萄糖,是全球最常見的測試之一。 由於全球糖尿病患者數量不斷增加以及各公司推出新產品,預計用於血糖檢測的 POC 診斷在預測期內將出現顯著增長。

糖尿病患病率的增加和便攜式診斷設備的引入預計將促進該細分市場的增長。 例如,國際糖尿病聯合會(IDF)報告稱,2021年全球20-79歲的成年人中,每10,000人中將有536,600.0人患有糖尿病,而到2030年,這一數字將上升至每1,000人中有642,800.0人。預計將增至到 2045 年每 1000 名成年人中有 783,700.0 人。 因此,越來越多的糖尿病患者受到關注,增加了對快速診斷的需求。 因此,越來越多的糖尿病患者增加了對 POC 診斷的需求。

此外,床旁 (POC) 診斷的引入及其使用的增加正在推動研究領域的增長。 例如,2022 年 5 月,英國醫療保健公司 LumiraDx 製造了一個支持測試菜單的診斷平台,宣布其 HbA1c 測試將獲得 CE 標誌,用於在護理點 (POC) 環境中篩查和監測糖尿病患者. 報告已獲得。 因此,POC 的推出也有助於所調查市場的增長。

因此,由於糖尿病患者人數的增加和新產品的推出,預計該細分市場在預測期內將出現顯著增長。

即時診斷市場-IMG1

北美預計在預測期內將顯著增長。

北美地區包括美國、加拿大和墨西哥。 由於主要市場參與者的存在以及慢性病和傳染病發病率的上升,預計該地區在預測期內將出現顯著增長。

最近的收購和產品發布促進了所研究市場的增長。 例如,2023 年 1 月,總部位於美國的 Heska Corporation 收購了 MBio Diagnostics, Inc。 Heska Corporation 製造、開發和銷售先進的動物診斷和專業保健產品,包括 POC 測試設備。 因此,此類收購正在推動該地區研究市場的增長。

此外,NOWDiagnostic 的 ADEXUSDx hCG Test 將於 2022 年 5 月用於定性檢測人全血、血漿或血清中的人絨毛膜促性腺激素 (hCG),並已獲得 USFDA 批准,可在美國上市。一個可以完成的測試。 這種免疫測定測試將幫助醫療保健專業人員在各種臨床和重症監護環境中及早發現妊娠。 因此,監管機構批准新的 POC 診斷有助於該地區研究市場的增長。

此外,該地區糖尿病和癌症等疾病患病率上升也促進了市場增長。 例如,根據加拿大糖尿病協會 2022 年 3 月發布的一份報告,該國的糖尿病呈積極上升趨勢,報告發佈時有 1170 萬加拿大人患有或未患糖尿病。另有近 570 萬加拿大人表示他們患有糖尿病糖尿病前期診斷。 這種日益增加的糖尿病負擔增加了對 POC 的需求,推動了被調查市場的增長。

同樣,2022 年,國際世界癌症研究基金會 (WCRF) 的一份報告列出了墨西哥診斷出的近 101,703 例癌症病例。 POC 還用於癌症的早期檢測,大量癌症患者有助於該地區研究市場的增長。

因此,預計主要市場參與者近期的收購、產品發布和慢性病發病率上升將在預測期內推動該地區的市場增長。

即時診斷市場-IMG2

床旁 (POC) 診斷行業概覽

床旁 (POC) 診斷市場競爭激烈,由多家大型企業組成。 就市場份額而言,目前少數大公司佔據市場主導地位。 主要市場參與者包括 Abbott Laboratories、Siemens Healthineers AG、Danaher Corporation(Beckman Coulter Inc)、Becton、Dickinson and Company、Institution Laboratory、Johnson and Johnson Inc、Nova Biomedical Corporation、Qiagen Inc、F. Hoffmann-La Roche Ltd、Biomeriux SA , ETC。

其他福利:

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 調查假設和市場定義
  • 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 慢性病和傳染病的患病率增加
    • 新型免疫測定技術獲得監管批准的數量增加
    • 技術進步和家庭 POC 設備的使用增加
  • 市場製約因素
    • 產品召回
    • 嚴格的監管政策和報銷問題
  • 波特五力
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(基於價值的市場規模)

  • 按產品分類
    • 血糖監測套件
    • 心血管代謝監測套件
    • 妊娠/生育力測試套件
    • 傳染病檢測試劑盒
    • 膽固醇測量條
    • 血液學檢測試劑盒
    • 其他產品
  • 最終用戶
    • 醫院和重症監護機構
    • 門診護理
    • 研究所
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation(Beckman Coulter Inc.)
    • Becton, Dickinson and Company
    • Instrumentation Laboratory
    • Johnson and Johnson Inc.
    • Nova Biomedical Corporation
    • Qiagen Inc.
    • F. Hoffmann-La Roche Ltd.
    • Biomeriux SA

第七章市場機會與未來趨勢

簡介目錄
Product Code: 55791

The point-of-care (POC) diagnostics market size is currently valued at USD 38.03 billion and is expected to register a CAGR of 9.8% during the forecast period.

The COVID-19 pandemic had a significant impact on the growth of the POC diagnostics market. For instance, an article published by the journal Cureus in August 2022 reported that with the emergence of COVID-19, testing became essential for containment and mitigation purposes, and this led to the development of rapid COVID-19 testing. Thus, the COVID-19 pandemic surged the demand for POC diagnostics. However, in the current scenario, due to the ease, affordability, reduced incidence of complications, and faster turn-around times of POC diagnostics, the demand for POC diagnostics is expected to witness significant growth over the forecast period.

The factors that are driving the growth of the studied market are the rising prevalence of chronic and infectious diseases, the increasing number of regulatory approvals for novel immunoassay techniques and technological advancements, and the rising usage of home-based POC devices.

The prevalence of chronic and infectious diseases, such as diabetes, rheumatism, and malaria, is increasing globally, which is propelling the demand for POC diagnostics. For instance, in December 2022, World Health Organization (WHO) reported that malaria is a life-threatening disease, and in the year 2021, there were an estimated 247 million cases of malaria worldwide. Similarly, an article published by NCBI in May 2021, reported that the global prevalence of rheumatoid arthritis (RA) was 460 per 100,000 population during 2020-2021. Thus, a high number of chronic and infectious diseases recorded globally is increasing the demand for rapid diagnostics, thereby increasing the demand for POC diagnostics and thus driving the growth of the studied market.

Moreover, the increasing number of regulatory approvals for novel immunoassay techniques, technological advancements, and the rising usage of home-based POC devices is expected to complement the growth of the studied market over the forecast period. For instance, in July 2022, BioGX launched CE-marked, three-gene multiplex POC COVID-19 test. These tests make use of BioGX's incredibly effective Xfree direct sample testing chemistry, which is present in their Xfree COVID-19 Direct RT-PCR assay, which has been cleared for emergency use by the United States Food and Drug Administration (USFDA). Thus, regulatory approvals for new product launches are contributing to the growth of the studied market.

Furthermore, an article published by Mylab Discovery Solutions in March 2022 reported that POC diagnostics, which are often characterized by being independent of laboratory infrastructure and being highly affordable, can greatly improve the accessibility of diagnostics. The article also quoted that for the people living in low and middle income countries where the healthcare distribution is quite uneven, the use of POC tests is growing as an important tool to increase diagnostic coverage of the population, and thus demand for POC is constantly increasing, thereby driving the growth of the studied market.

Thus, due to the rising prevalence of chronic and infectious diseases, the increasing number of regulatory approvals for novel immunoassay techniques and technological advancements, and the rising usage of home-based POC devices. However, factors such as product recall incidence by the major players in the market, stringent regulatory policies by the governments, and reimbursement issues will impede the growth of the POC diagnostics market during the forecast period.

Point of Care Diagnostics Market Trends

Blood Glucose Testing is Expected to Witness Significant Growth Over the Forecast Period.

A blood glucose test measures the glucose in the blood, and this is one of the most common tests done across the globe. Blood glucose testing POC diagnostics is expected to witness significant growth over the forecast period owing to rising diabetes cases recorded globally and the new product launches of the company.

The growing prevalence of diabetes and the introduction of portable diagnostic equipment are expected to boost segment growth. For instance, in 2021, International Diabetes Federation (IDF) reported that globally in the year 2021, a total of 536,600.0 per 10000 adults aged between (20-79) years were suffering from diabetes, and this number is expected to increase to 642,800.0 per 1000 adults by 2030 and 783,700.0 per 1000 adults by 2045. Thus, rising diabetes cases are a matter of concern, and there is increasing demand for rapid diagnostics. Thus, rising diabetes cases are increasing the demand for POC diagnostics.

Furthermore, the introduction of point-of-care diagnostics and its increasing use is driving the growth of the studied segment. For instance, in May 2022, LumiraDx, a UK-based healthcare company that manufactures a diagnostic platform to support a menu of tests reported that its HbA1c test received a CE mark for the screening and monitoring of people with diabetes in the point of care (POC) setting. Thus, the launch of such POC is also contributing to the growth of the studied market.

Thus, due to the rising diabetes cases and new product launches, the segment is expected to witness significant growth over the forecast period.

Point of Care Diagnostics Market - IMG1

North America is Expected to Witness a Significant Growth Over the Forecast Period.

North America region consists of the United States, Canada, and Mexico. The region is expected to witness significant over the forecast period due to the presence of key market players and the rising incidence of chronic and infectious diseases.

The recent acquisition and product launches are contributing to the growth of the studied market. For instance, in January 2023, Heska Corporation, a US-based company and a global provider of advanced veterinary diagnostic and specialty products and solutions, acquired MBio Diagnostics, Inc. Heska Corporation manufactures, develops, and sells advanced veterinary diagnostic and specialty healthcare products, including POC testing instruments. Thus such acquisitions are driving the growth of the studied market in the region.

Additionally, in May 2022, NOWDiagnostic's ADEXUSDx hCG Test was used for the qualitative detection of human chorionic gonadotropin (hCG) in human whole blood, plasma, or serum received the USFDA clearance, and the test available in the United States. This immunoassay test is an early detection aid for pregnancy for healthcare professionals in a variety of clinical and critical care settings. Thus, such clearance of new POC diagnostics by regulatory agencies is contributing to the studied market's growth in the region.

Moreover, the rising prevalence of diseases, such as diabetes and cancer, in the region is contributing to the market's growth. For instance, as per a report by the Canadian Diabetes Association published in March 2022, diabetes is increasing aggressively in the country, and by the time the report was published, stated that 11.7 million Canadians were living with diabetes or prediabetes, among which is nearly more than 5.7 million Canadians were living with diagnosed diabetes. Such an increasing burden of diabetes is increasing the demand for POC and thus driving the growth of the studied market.

Similarly, in the year 2022, the report of the World Cancer Research Fund International (WCRF) stated that nearly 101,703 cancer cases were diagnosed in Mexico. The POC is also used for the early detection of cancer, and the high number of cancer cases contributes to the growth of the studied market in the region.

Thus, the recent acquisition between the key market players, product launches, and the rising incidence of chronic diseases is expected to drive the growth of the market in the region over the forecast period.

Point of Care Diagnostics Market - IMG2

Point of Care Diagnostics Industry Overview

The point-of-care diagnostics market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. Some of the major players in the market are Abbott Laboratories, Siemens Healthineers AG, Danaher Corporation (Beckman Coulter Inc.), Becton, Dickinson and Company, Instrumentation Laboratory, Johnson and Johnson Inc., Nova Biomedical Corporation, Qiagen Inc., F. Hoffmann-La Roche Ltd., and Biomeriux SA.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic and Infectious Diseases
    • 4.2.2 Increasing Number of Regulatory Approvals for Novel Immunoassay Techniques
    • 4.2.3 Technological Advancements and Rising Usage of Home-based POC Devices
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls
    • 4.3.2 Stringent Regulatory Policies and Reimbursement Issues
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Glucose Monitoring Kit
    • 5.1.2 Cardio-metabolic Monitoring Kit
    • 5.1.3 Pregnancy and Fertility Testing Kit
    • 5.1.4 Infectious Disease Testing Kit
    • 5.1.5 Cholesterol Test Strip
    • 5.1.6 Hematology Testing Kit
    • 5.1.7 Other Products
  • 5.2 By End User
    • 5.2.1 Hospital and Critical Care Setting
    • 5.2.2 Ambulatory Care Setting
    • 5.2.3 Research Laboratory
    • 5.2.4 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Siemens Healthineers AG
    • 6.1.3 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.4 Becton, Dickinson and Company
    • 6.1.5 Instrumentation Laboratory
    • 6.1.6 Johnson and Johnson Inc.
    • 6.1.7 Nova Biomedical Corporation
    • 6.1.8 Qiagen Inc.
    • 6.1.9 F. Hoffmann-La Roche Ltd.
    • 6.1.10 Biomeriux SA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS